Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular characterization of colorectal cancer related peritoneal metastatic disease [scRNA-seq]

ABSTRACT: We present acomprehensive molecular characterization of a cohort of 5 patients with peritoneal metastasis

ORGANISM(S): Homo sapiens

PROVIDER: GSE183916 | GEO | 2022/06/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Molecular characterization of colorectal cancer-related peritoneal metastatic disease [RNA-seq]

Project description:We present a comprehensive molecular characterization of a cohort of 52 patients with peritoneal metastasis

2022-06-01 | GSE183202 | GEO

Molecular characterization of colorectal cancer related peritoneal metastatic disease [scRNA-seq]

Project description:Molecular characterization of colorectal cancer related peritoneal metastatic disease [scRNA-seq]

| PRJNA762334 | ENA

Molecular characterization of colorectal cancer-related peritoneal metastatic disease

Project description:Molecular characterization of colorectal cancer-related peritoneal metastatic disease

| PRJNA762330 | ENA

Molecular characterization of colorectal cancer-related peritoneal metastatic disease [RNA-seq]

Project description:Molecular characterization of colorectal cancer-related peritoneal metastatic disease [RNA-seq]

| PRJNA759609 | ENA

Molecular characterization of colorectal cancer-related peritoneal metastatic disease

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-06-01 | GSE183917 | GEO

Proteomic characterization of metastatic colorectal cancer

Project description:To characterize metastatic progression of colorectal cancer, we performed mass spectrometry-based proteome analysis using large clinical cohort samples.

2024-01-16 | PXD031705 | Pride

Molecular subtypes of malignant peritoneal mesothelioma

Project description:Malignant Peritoneal Mesothelioma (PeM) is a rare but frequently fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no targeted therapies for PeM yet exist. This study performs comprehensive integrative analysis of genome, transcriptome, and proteome of treatment-naïve PeM tumors with the aim of identifying mesothelioma-related molecular alterations and potentially identifying novel treatment strategies.

2018-12-11 | PXD008873 | Pride

Molecular Tools for Metastatic Colorectal Cancer Characterization

Project description:In our recent publication [1], we have explored at the molecular level the consequences of reovirus administration to patients with KRAS mutated colorectal cancer (CRC). This was the first reported study where transcriptome assay was performed on KRAS mutated CRC patients receiving reovirus (pelareorep) therapy. Using peripheral mononuclear cells as a tumor surrogate, we have identified several hundred genes that were significantly altered in a transcriptome assay of patients receiving pelareorep serving as their own controls (pre and post reovirus administration) and compared to untreated controls [2]. We focused primarily on 884 immune related genes and published the data for genes with significance probability of 0.001 (1 in thousand for a perfect random occurrence). Samples were collected at 48 hours, day 8 and day 15 post reovirus administration and compared for dynamic gene expression alterations over time. Using PBMC we also performed flow cytometry, cytokine ELISA, immunohistochemistry, and determination of the expression level of CRC specific microRNA miR-29a-3p. Our data supports the therapeutic competence of reovirus and identifies the four major ways by which it exerts its antitumor effects.

| S-EPMC7793569 | biostudies-literature

Deciphering metastatic route-specific signals and their microenvironment interactions in peritoneal metastasis of gastric cancer

Project description:Gastric cancer (GC) constitutes a significant cause of cancer-related mortality worldwide, with metastatic patterns including hematogenous, peritoneal, and ovarian routes. Although GC gene expression patterns have been extensively researched, the metastasis-specific gene expression landscape remains largely unexplored. This study undertook a whole transcriptome sequencing analysis of 66 paired primary and metastatic (hematogenous, peritoneal, or ovarian) GC tumors from 14 patients, leading to the identification of 122 unique metastasis-specific epithelial-mesenchymal transition (msEMT) genes. These genes demonstrated varying expression patterns depending on the metastatic route, suggesting route-specific molecular mechanisms in GC metastasis. High expression of msEMT genes in primary tumors was associated with more frequent CDH1 mutations, the genomically stable subtype, and poor prognosis in The Cancer Genome Atlas GC cohort. This association was further corroborated by poor prognosis and high predictive performance for peritoneal or ovarian recurrence in two independent cohorts (GSE66229; n=300, GSE84437; n=433). Single-cell RNA sequencing analysis of primary tumors (GSE167297) and four independent ascites samples from GC patients revealed that msEMT genes were predominantly expressed in diverse fibroblast sub-populations, rather than cancer cells. This study illuminates the route-specific mechanisms and underlines the significance of msEMT genes and cancer-associated fibroblasts in GC metastasis, highlighting potential directions for future research.

2024-07-01 | GSE237876 | GEO

Gender- and Age-Based Characterization and Comparison of the Murine Primary Peritoneal Mesothelial Cell Proteome

Project description:Raw and processed data in support of manuscript "Gender- and Age-Based Characterization and Comparison of the Murine Primary Peritoneal Mesothelial Cell Proteome" Zhikun Wang1,2, Yueying Liu1,2, Reihaneh Safavisohi1,2, Marwa Asem1,2, Daniel Hu1, Mary Sharon Stack1,2,3, Matthew M. Champion1,3 1Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame IN 46556; 2Harper Cancer Research Institute, University of Notre Dame, South Bend IN 46617

2023-06-09 | MSV000092134 | MassIVE